This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Allergan Bids for Inamed

An Allergan acquisition of Inamed would represent diversification, adding for instance breast implants, as well as fortification of its skin-care business, says Ken Kulju, of Credit Suisse First Boston. He has a neutral rating on Allergan. Additionally, he applauds Allergan's Inamed bid as a clever defense against a Medicis challenge to the Botox franchise.

He doesn't own shares of the companies. However, his firm says it does or seeks to do business with companies covered in its research reports.

The potential sales impact of silicone-gel implants can't be ignored. However, U.S. sales of these implants have been restricted since 1992 to a handful of uses, such as for women undergoing breast reconstruction after mastectomies and women whose implants had ruptured. The restrictions reflect tougher FDA requirements that manufacturers provide long-term safety data to support applications for their devices.

Both Inamed and Mentor sell implants in foreign markets for cosmetic purposes. They also sell saline-filled implants in the U.S. for cosmetic purposes.

Allergan, based in Irvine, Calif., has a market capitalization of $12.67 billion vs. Medicis' $1.45 billion. Allergan bragged that its offer for Inamed is superior because it features more cash, greater liquidity, "with closure at least as fast as or faster than the Medicis transaction, and with a stronger pro forma balance sheet." Medicis had no immediate comment.

"It's a better strategic fit," says Jayson T. Bedford of Adams Harkness who maintained his buy rating on Inamed. If Allergan prevails, it will have to pay a $90 million break-up fee to Medicis, Bedford says. He doesn't own shares. His firm says it intends to seek or receive investment-banking fees from companies mentioned in research reports.

That's a price worth paying, Bedford says in a research note, because Allergan's offer is "superior from both a financial and strategic sense." It's always possible that Medicis could raise its bid, "but we feel Allergan has deeper pockets and seems committed to this opportunity."

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs